Skip to main content

SNY · Sanofi

Track SNY — free
$45.81 -1.31 (-2.78%)
Market Cap
$113.15B
Shares
2.40B
Volume · Nov 19 1.58M Avg daily vol (3M) 3.32M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$47.12 Open$47.41 Day$47.10–47.76 52W close$39.12–50.66 Avg vol 30d4.1M Short int12.3M · 0.5% of shares · 2.9d Short vol21% Last earningsOct 30, 2026 DataJan 2020–Nov 2026

Up next

Jan 28, 2027 Scheduled · in 10 wks

Latest documents

2026
Oct 30
Earnings call
Q3 sales rise 14.3%, new launches reach 2.2 billion euros

Sanofi reported Q3 total sales of 14.4 billion euros, up 14.3%, with new launches contributing approximately 2.2 billion euros, up 19.2%. Dupixen sales reached 5.7 billion euros, while the pipeline comprised 61 development projects and 36 new molecules.

Read from the first part of this long document
5 source passages
Our total sales reached 14.4 billion euros, up 14.3% versus last year. Sales of new launches reached approximately 2.2 billion euros in Q3, a growth of 19.2%. Dupixen sales reach 5.7 billion euros in the quarter, and more than 1.5 million patients are currently under treatment globally. Our pipeline comprises 61 development projects across pharma and vaccines, including 36 new molecules. Sanofi already has a very significant investment in R&D. Open the document at this passage
Oct 30
Current report 6-K
Q3 sales up 14.3% at CER; 2026 sales guidance raised

Sanofi reported Q3 2026 net sales of €14,444 million, up 14.3% at CER, and business EPS of €3.55, up 19.6% at CER. It raised 2026 guidance: sales growth is now expected at a low-teens percentage at CER.

Read from the first part of this long document
3 source passages
Net sales were €14,444 million in Q3 2026 and increased by 16.2% (14.3% at CER) from €12,434 million in Q3 2025. Business EPS was €3.55, up by 19.6% at CER; 22.0% at actual exchange rates; IFRS EPS €2.52 2026 guidance is upgraded: sales are expected to grow by a low-teens percentage at CER. Open the document at this passage
Oct 26
Current report 6-K
Current report

Sanofi broke ground on a new insulin manufacturing facility in Frankfurt, Germany, with a 36,000-square-meter footprint and full insulin active pharmaceutical ingredient production planned for 2032 once fully licensed.

Oct 1
Current report 6-K
Current report

Sanofi and Regeneron expanded their alliance to co-develop four long-acting antibodies, including REGN20423. Regeneron will receive $1 billion upfront and up to an additional $7 billion in milestones; the companies will share development and commercialization costs and split profits 50:50.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$53.48B
Trailing 12 months
Net income (TTM)
$4.62B
Trailing 12 months
Revenue growth YoY
+6.2%
Year over year
Operating margin
12.5%
Trailing 12 months
P / E (TTM)
24.5
Trailing earnings · reciprocal yield 4.1%
FCF yield
—
TTM · current market cap
Return on invested capital
5.3%
Trailing 12 months
Net cash
−$13.59B
Latest balance sheet
Dividend yield
5.1%
Trailing 12 months
Shares change YoY
-2.4%
Year over year · fewer shares
Price change (1Y)
-7.0%
Trailing year
Short interest
0.5%
Latest settlement · 2.9 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Strong Sentiment Bearish Fundamentals Limited Quant / Vol Very Low
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +6%
above
Price vs 50-day avg +10%
above
RSI (14) 63
neutral
MACD trend Positive
52-week position 69%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +15%
trailing
6-month return +8%
trailing
YTD return −3%
this year
Relative strength +11%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $43 › 200d $44 — 200d above 50d
Institutional flow Distributing
-6% holders QoQ · +70 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.51% of shares out · ▲ +5.9% MoM · 2.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
690 holders — near 3-yr low, contrarian setup
Squeeze score 48
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very Low
Volatility 24%
annualized · 1-yr
Max drawdown −23%
past year
ATR 2.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+6% Bullish
Price vs 50-day avg
+10% Bullish
RSI (14)
63 Neutral
MACD trend
Positive Bullish
52-week position
69% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $43 › 200d $44 — 200d above 50d
Institutional flow Distributing
-6% holders QoQ · +70 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.51% of shares out · ▲ +5.9% MoM · 2.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
690 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $39 Now $47 · 69% Range high $51
vs 200-day avg +6% vs 50-day avg +10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SNY
Sanofi
this stock
$113.15B -2.8% — — 0.5%
LLY
ELI LILLY & Co
$1.30T +28.7% +44.7% 44.9 0.8%
JNJ
Johnson & Johnson
$656.47B +31.8% +6.0% 41.4 0.7%
ABBV
AbbVie Inc.
$505.56B +25.2% +8.6% 49.2 0.9%
MRK
Merck & Co., Inc.
$339.66B +30.9% +1.3% 142.0 1.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
690
% held
7.4%
Net QoQ
-12.9M sh
Top holder
Dodge & Cox
Held Float
View
Held by Funds
Fund positions
103
View
Short & Settlement
Short Interest Rising
Shares short
12.3M
Days to cover
2.9d
Change
+679.6K sh
View
Short Volume
Short vol %
21%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
2.5K
Value
$107.5K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
43.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Alan Armstrong
Amount
$15.0K–$50.0K
Traded
Mar 30, 2026
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 30, 2026
This year
39

Sanofi reported Q3 2026 net sales of €14,444 million, up 14.3% at CER, and business EPS of €3.55, up 19.6% at CER. It raised 2026 guidance: sales growth is now expected at a low-teens percentage at CER.

View
Earnings & Events
Webcasts Upcoming
Next webcast
Jan 28, 2027
Last webcast
Oct 30, 2026
View
Investor Relations
Upcoming events
4
View

Performance

5D 20D 120D MTD YTD
SNY -2.7% +15.0% +7.9% +6.3% -2.8%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +1.2% +20.6% +11.4% +9.7% -9.9%

Capital returns

Latest dividend
$2.422 / share · ex May 4, 2026
Raised 9.5%
Paid (TTM)
$2.422 / share · 1 payout
Dividend yield (TTM, derived)
— · history filling in
Full dividend history

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1121404 CUSIP 80105N105 13F (30d) 674 filings 606 filers Visit website Investor relations